Neocell

NEOLAP Injectable Suspension

COMPOSITION
Organs suspension with at least 128 UA (agglutinant units) per unit 150 mg   Active principle

Adjuvant :
Aluminium hydroxide (expressed as aluminium oxide)  5mg               Immune adjuvant

IMMUNOLOGICAL PROPERTIES
NEOLAP, inactivated vaccine against Viral Hemorrhagic Disease in rabbits, is a clear measure of Medical Prophylaxis. Chinese experience clearly demonstrated that the against Viral Hemorrhagic Disease in rabbits could be controlled by slaughtering of affected animals, strict quarantine and especially by vaccination. It is a tissue suspension, which is obtained by inoculation in a susceptible animals and collection of the target organs, when animals develop the experimental infection and come to a drying state. The b-propiolactone has been chosen as inactivated agent because of two quite significant facts: 1) Experimental use of this product has demonstrated its efficiency as inactivating agent of the virus, keeping the immunizing power of the suspension, once it was inactivated. 2) b-Propiolactone admits a laboratory test to verify that it has not suffered degradation process due to a partial hydrolyze before its use and so it is totally active for its duty. Aluminium hydroxide has been chosen as immune adjuvant of the vaccine, because it stimulates the immune response and facilitates the stability of the suspension, being aware that the particle nature of antigen can in some cases make difficult the stability of any other options, like oily emulsion. The demonstrative safety, at laboratory level as well as at fields’ vaccinations, has been satisfactory, which comes to confirm the adequate inactivation of the virus by the inactivating agent, besides the lack of reactions derived from the immune adjuvant or from its non-suitability. At serological level, the use of the specialty leads to a soon seroconversion, reaching titles of 1/320 in the inhibition reaction of hemagglutination, between the fourth and the seventh day post-inoculation. The sero-conversion is kept at those levels until for-six months since the vaccination.

TARGET SPECIES
Only rabbits. No hares

INDICATIONS
NEOLAP is intended for the prevention of Viral Hemorrhagic Disease in rabbits.

DOSAGE AND METHOD OF ADMINISTRATION
Vaccination of breeding or reposition animals
Dosage: 1ml by subcutaneous route, using sterile material. Annual re-vaccination.
Fattening animals
Dosage: 0,5ml by subcutaneous route, using sterile material.

CONTRA INDICATIONS
Not described

UNDESIRABLE EFFECTS
In some animals, rectal temperature can increase 1-1,50 C, in the two first days post vaccination. A little redness can appears in the inoculation point, but it disappears after 5-7 days.
Redness characteristics:               Size:  More or less, 2mm of diameter.                     Consistence:  Little induration of the skin

INTERACTION WITH OTHER MEDICAMENTS
Because it is an inactivated vaccine, it is not foreseeable its interaction with other immunological products, in case of a parallel application. The post-vaccinal immune response could be affected by the use of immunosuppressant medicines, such as corticoids, during the days before or after the vaccination.

INCOMPATIBILITY
Do not mix with any other immunological product.

OVERDOSE
Not mentioned

USE DURING PREGNANCY AND LACTATION
In prophylaxis treatment, if the proposed vaccination program is followed, animals must be vaccinated before they begin their reproductive life.
In annual re-vaccination, or in other vaccination programs that can be carried out, most animals may be pregnant and/or suckling. Bearing in mind the experimental results, as well as its field use, it can be deduced that the product presents no effect on any physiological states. Handling of pregnant animals during the vaccination process must be careful.

SPECIAL PRECAUTIONS FOR USE
Its application does not need specially precautions, except for the normal ones about asepsis and protection against possible undercurrent infectious process.

SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE PRODUCT TO ANIMALS
Not required. If involuntary inoculation occurs, it may appear a light and a bit painful inflammatory reaction in the injection point, that comes to an end in one or two days.

WITHDRAWAL TIME
Zero days

STORAGE
The product remains stable for 24 months when it is stored between 2^o C and 8^o C. Once started the extraction of the content this must be used uninterruptedly.

SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY:
The vials and any residual content must be eliminated according to current rules about toxic and dangerous waste type IV

PACKAGE
Vials of 2, 10, 25, 50, 100 and 250 doses with their correspondent diluents.